EUCTR2008-006146-26-DK进行中（未招募）不适用
A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and radiotherapy followed by placebo and temozolomide in patients with newly diagnosed glioblastoma - AVAGLIO
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 921
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed informed consent
- •2. Age greater than or equal to 18 years
- •3. Present with newly diagnosed supratentorial Glioblastoma (GBM) with a tissue diagnosis that has been established following either a surgical resection or biopsy. This includes treatment-naïve -(chemotherapy and radiotherapy)- patients with prior diagnosis of a lower grade astrocytoma that has been upgraded to a histologically verified GBM
- •4. Craniotomy or intracranial biopsy site must be adequately healed, free of drainage or cellulitis, and the underlying cranioplasty must appear intact at the time of randomisation. Study treatment should be initiated = 28 days and = 49 days following the last surgical procedure (including biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity)
- •5. WHO performance status = 2
- •6. Patient must have at least 1 formalin fixed paraffin embedded tumour tissue block representative of glioblastoma available for pathology central review and analysis of MGMT status. If tumour block is not available or not of adequate quality, sufficient pathology material, representative of glioblastoma, must be available for central review.
- •7. Stable or decreasing corticosteroids dose within 5 days prior to randomization
- •8. Adequate hematological function:
- •Absolute neutrophil count (ANC) = 1.5 x 1'000'000'000/L
- •Platelet count = 100 x 1'000'000'000/L
- •Haemoglobin = 10 g/dL (may be transfused to maintain or exceed this level)
- •9. Adequate liver function
- •Total bilirubin = 1.5 x ULN
- •AST and ALT = 2.5 x ULN
- •10. Adequate renal function
- •Creatinine = 1.25 x ULN
- •Urine dipstick for proteinuria < 2+. Patients discovered to have = 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate = 1.0 g of protein in 24 hours
- •Urine protein/creatinine ratio (UPC) = 1.0
- •11. International normalized ratio (INR) or PT (secs) and activated partial thromboplastin time (aPTT):
- •in the abscence of therapeutic intent to anticoagulate the subject: INR=1.5 or PT=1.5 x ULN and aPTT=1.5 x ULN
- •in the presence of therapeutic intent to anticoagulate the subject: INR or PT and aPTTwithin therapeutic limits (according to the medical standard in the institution)
- •NOTE: Use of full-dose anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose of anticoagulants for at least two weeks before randomization. As per ASCO guidelines, LMWH should be the preferred approach
- •12. Willing and able to comply with the protocol as judged by the investigator
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 663
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 258
排除标准
- •Disease and Treatment History
- •1. Evidence of recent hemorrhage on postoperative MRI of the brain. However, patients with clinically asymptomatic presence of hemosiderin, resolving hemorrhagic changes related to surgery, and presence of punctate hemorrhage in the tumor are permitted entry into the study
- •2. Previous centralized screening for MGMT status for enrolment into a clinical trial
- •3. Any prior chemotherapy (including carmustine-containing wafers (Gliadel®) or immunotherapy (including vaccine therapy) for glioblastomas and low grade astrocytomas
- •NOTE: 5-aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) administered prior to surgery to aid in optimal surgical resection is not considered a chemotherapy agent
- •4. Any prior radiotherapy to the brain or prior radiotherapy resulting in a potential overlap in the radiation field
- •Bevacizumab related Exclusion Criteria
- •5. Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 m Hg)
- •6. Prior history of hypertensive crisis or hypertensive encephalopathy
- •7. New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix 6)
- •8. History of myocardial infarction or unstable angina within 6 months prior to randomization
- •9. History of stroke or TIAs within 6 months prior to randomization
- •10.Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to randomization
- •11.History of = grade 2 haemoptysis according to the NCI-CTC criteria within 1 month prior to randomization
- •12.Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)
- •13.Major surgical procedure, open biopsy, intracranial biopsy, ventriculoperitoneal shunt or significant traumatic injury within 28 days prior to randomization
- •14.Core biopsy (excluding intracranial biopsy) or other minor surgical procedure within 7 days prior to randomization. Placement of a central vascular access device (CVAD) if performed within 2 days prior to bevacizumab/placebo administration
- •15.History of abdominal fistula or gastrointestinal perforation within 6 months prior to randomization
- •16.History of intracranial abscess within 6 months prior to randomization
- •17.Serious non-healing wound, active ulcer or untreated bone fracture
- •18.Pregnant or lactating females. NOTE: Serum pregnancy test to be assessed within 7 days prior to study treatment start
- •19.Fertile women < 2 years after last menstruation and men (surgically sterilized and of childbearing potential) unwilling or unable to use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly)
- •General Exclusion Criteria
- •20.Any other malignancy within 5 years prior to randomization, except for adequately controlled limited basal cell carcinoma of the skin, squamous carcinoma of the skin or carcinoma in situ of the cervix
- •21.Evidence of any active infection requiring hospitalization or IV antibiotics within 2 weeks prior to randomization
- •22.Patients who have any other disease, either metabolic or psychological, or who have any evidence on clinical examination or special investigations (including a laboratory finding) which gives reasonable suspicion of a disease or condition that contraindicates the use of the investigational drug, or that may affect the patient’s c
研究者
相似试验
进行中（未招募）
不适用
A study comparing bevacizumab with placebo when added to the current standard of treatment (temozolomide and radiotherapy, followed by temozolomide) in patients with a type of newly diagnosed brain tumor named GlioblastomaMedDRA version: 14.1Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)GlioblastomaEUCTR2008-006146-26-NLF. Hoffmann-La Roche Ltd921
已完成
不适用
To assess the effectiveness of study medication LactoSporein comparison with Placeboi.e. a substance with no effect in patients suffering from Major Depressive Disorder in Inflammatory Bowel Syndrome.CTRI/2015/05/005754Sami labs Limited40
进行中（未招募）
不适用
A randomized, double blind, placebo controlled, multicenter study to determine the effect of QVA149 on mean 24-hours heart rate in patients with Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary DiseaseMedDRA version: 9.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2007-003670-25-FRovartis Pharma AG250
进行中（未招募）
不适用
A study comparing bevacizumab with placebo when added to the current standard of treatment (temozolomide and radiotherapy, followed by temozolomide) in patients with a type of newly diagnosed brain tumor named GlioblastomaMedDRA version: 17.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)GlioblastomaEUCTR2008-006146-26-DEF. Hoffmann-La Roche Ltd921
进行中（未招募）
不适用
A randomized, double blind, placebo controlled, multicenter study to determine the effect of QVA149 on mean 24-hours heart rate in patients with Chronic Obstructive Pulmonary Disease (COPD) - NDChronic obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10061877Term: Obstructive airways disorderEUCTR2007-003670-25-ITOVARTIS FARMA250